Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
Rangering i aksjer #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Aksjekurs
$17.82
Sist synkronisert: 2026-09-11
Markedsverdi
$32.43B
Endring (1 dag)
0.83%
Endring (1 år)
-25.31%
Land
JP
Handel Daiichi Sankyo Company, Limited (4568)

Kategori

Inntekter for Daiichi Sankyo Company, Limited (4568)
Inntekter i Jun 2026 TTM: $1.65B
Ifølge Daiichi Sankyo Company, Limited sine nyeste økonomiske rapporter er selskapets nåværende resultat $1.65B. I 2024 hadde selskapet et resultat på $1.57B, en økning sammenlignet med resultatet i 2023, som var $955.41M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Daiichi Sankyo Company, Limited fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $1.65B -30.33%
2025 $2.37B 51.37%
2024 $1.57B 64.05%
2023 $955.41M 58.24%
2022 $603.78M -9.78%
2021 $669.24M -49.03%
2020 $1.31B 69.80%
2019 $773.25M 1.40%
2018 $762.56M -3.25%
2017 $788.16M -27.54%
2016 $1.09B 63.21%
2015 $666.47M -31.10%
2014 $967.36M -1.02%
2013 $977.31M 139.07%
2012 $408.79M -71.86%
2011 $1.45B 39.41%
2010 $1.04B -133.26%
2009 $-3.13B -287.21%
2008 $1.67B 55.54%
2007 $1.08B -7.55%
2006 $1.16B 60.36%
2005 $725.65M -8.51%
2004 $793.11M 29.61%
2003 $611.93M 0.45%
2002 $609.17M -8.18%
2001 $663.43M -26.55%
2000 $903.21M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$33.59B 1,932.41%
US
$25.20B 1,424.32%
US
$8.70B 426.28%
US
$21.39B 1,193.96%
CH
$5.95B 259.84%
US